Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka

Yo Ichi Yamashita, Ken Sirabe, Ken Kawabe, Nao Fujimori, Terumasa Hisano, Yoshinobu Okabe, Takumi Akiyama, Toshiharu Ueki, Hikoyuki Horiuchi, Hiroya Yamaguchi, Tetsuhide Ito, Hideya Suga, Akihiro Funakosi

Research output: Contribution to journalArticle

Abstract

The standard chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers is considered gemcitabine plus cisplatin (Gc) on the basis of favorable results reported in the ABC-02 study from the UK and the BT22 study from Japan. However, the GC cohort of the BT22 study consisted of only 42 patients, and we considered it necessary to confirm the effectiveness and safety of GC chemotherapy in a multicenter prospective observational study in Fukuoka. Thirty- seven patients were enrolled in this study, including two patients with recurrent disease. The median patient age was 67.5 years (range, 43-84 years). Twelve patients had intrahepatic cholangiocarcinoma, 13 patients had extrahepatic cholangiocarcinoma, and 12 patients had gallbladder cancer. The median survival time (MST) was 14.9 months, the 1-year survival rate was 54.5%, and the median progression free survival (PFS) was 7.7 months. No chemotherapy-related deaths occurred, and Grade 3/4 adverse events were mainly hematological events including leucopenia in 13 (35.1%) patients and neutropenia in 12 (32.4%). The MST, 1-year survival rate, median PFS, and rate of Grade 3/4 adverse events in our study were similar to those of the BT22 study. In conclusion, this multicenter prospective observational study confirms the effectiveness and safety of GC chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers.

Original languageEnglish
Pages (from-to)1185-1189
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Volume42
Issue number10
Publication statusPublished - Oct 2015

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka'. Together they form a unique fingerprint.

  • Cite this

    Yamashita, Y. I., Sirabe, K., Kawabe, K., Fujimori, N., Hisano, T., Okabe, Y., Akiyama, T., Ueki, T., Horiuchi, H., Yamaguchi, H., Ito, T., Suga, H., & Funakosi, A. (2015). Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka. Japanese Journal of Cancer and Chemotherapy, 42(10), 1185-1189.